INHIBIKASE THERAPEUTICS INC (IKT) Stock Price, Quote, News and Overview

Company Profile

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in developing protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. The company is headquartered in Atlanta, Georgia and currently employs 8 full-time employees. The company went IPO on 2020-12-23. The firm is focused on developing therapeutics for Parkinson’s disease and related disorders. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program risvodetinib (also known as IkT-148009), an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson’s disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. Its multi-therapeutic pipeline is pursuing Parkinson’s-related disorders of the brain and GI tract, orphan indications related to Parkinson’s disease such as Multiple System Atrophy, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate. The Company’s RAMP medicinal chemistry program has identified a number of follow-on compounds to IkT-148009 to be potentially applied to other cognitive and motor function diseases of the brain.

Company Info

INHIBIKASE THERAPEUTICS INC

3350 Riverwood Parkway Se, Suite 1900

Atlanta GEORGIA 30339 US

CEO: Milton H. Werner

Employees: 9

Company Website: https://www.inhibikase.com/

Investor Relations: http://www.inhibikase.com/investors

Phone: 16783923419